Milestone Scientific (MLSS)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • AMEX
Market Cap: $27.82M
Last updated: Nov 17, 2026 at 11:05 AM ET
Milestone Scientific (MLSS) Earnings: Report Dates and Results
Milestone Scientific (MLSS) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Milestone Scientific reported EPS of -$0.01, in line with the -$0.01 estimate. It beat the EPS estimate in 0 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MLSS has an expected report date of Mar 29, 2027.
MLSS Earnings Call
The latest MLSS earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 40 quarters below that had an estimate, MLSS beat 9, missed 17 and matched 14. Revenue for the quarter ended Sep 30, 2026 was $2.22M, down 5.9% from $2.36M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.01 | -$0.01 | -$0.01 - -$0.01 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Nov 13, 2026 | $2.22M |
| Jun 30, 2026 | -$0.01 | -$0.01 | -$0.01 - -$0.01 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Aug 13, 2026 | $2.84M |
| Mar 31, 2026 | -$0.01 | -$0.01 | -$0.02 - -$0.01 | 0.00% | In line | N/A | 2 | 0 up, 1 down | May 13, 2026 | $2.16M |
| Dec 31, 2025 | -$0.01 | -$0.01 | -$0.02 - -$0.01 | 0.00% | In line | N/A | 2 | 0 up, 1 down | Mar 31, 2026 | $2.06M |
| Sep 30, 2025 | -$0.01 | -$0.01 | -$0.01 - -$0.01 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Nov 13, 2025 | $2.36M |
| Jun 30, 2025 | -$0.02 | -$0.01 | -$0.01 - -$0.01 | -100.00% | Miss | N/A | 1 | 0 up, 0 down | Aug 14, 2025 | $2.32M |
| Mar 31, 2025 | -$0.02 | -$0.01 | -$0.01 - -$0.01 | -100.00% | Miss | N/A | 1 | 0 up, 0 down | Apr 15, 2025 | $2.23M |
| Dec 31, 2024 | -$0.03 | -$0.01 | -$0.01 - -$0.01 | -200.00% | Miss | N/A | 1 | 0 up, 0 down | Mar 28, 2025 | $2.01M |
| Sep 30, 2024 | -$0.02 | -$0.01 | -$0.01 - -$0.01 | -100.00% | Miss | N/A | 1 | 0 up, 0 down | Nov 14, 2024 | $2.51M |
| Jun 30, 2024 | -$0.02 | -$0.01 | -$0.01 - -$0.01 | -100.00% | Miss | N/A | 1 | 0 up, 0 down | Aug 14, 2024 | $1.85M |
| Mar 31, 2024 | -$0.02 | -$0.02 | N/A | 0.00% | In line | N/A | N/A | N/A | May 15, 2024 | $2.25M |
| Dec 31, 2023 | -$0.03 | -$0.02 | N/A | -50.00% | Miss | N/A | N/A | 0 up, 0 down | Mar 29, 2024 | $2.26M |
| Sep 30, 2023 | -$0.02 | -$0.02 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Nov 14, 2023 | $2.06M |
| Jun 30, 2023 | -$0.03 | -$0.02 | N/A | -50.00% | Miss | N/A | N/A | 0 up, 0 down | Aug 15, 2023 | $2.91M |
| Mar 31, 2023 | -$0.02 | -$0.03 | -$0.03 - -$0.03 | +33.33% | Beat | N/A | 1 | 0 up, 0 down | May 11, 2023 | $2.60M |
| Dec 31, 2022 | -$0.03 | -$0.03 | -$0.03 - -$0.03 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Mar 31, 2023 | $2.24M |
| Sep 30, 2022 | -$0.03 | -$0.03 | -$0.03 - -$0.03 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Nov 15, 2022 | $2.22M |
| Jun 30, 2022 | -$0.04 | -$0.03 | N/A | -33.33% | Miss | N/A | N/A | 0 up, 0 down | Aug 16, 2022 | $1.65M |
| Mar 31, 2022 | -$0.03 | -$0.03 | -$0.03 - -$0.03 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Apr 1, 2022 | $2.70M |
| Dec 31, 2021 | -$0.02 | -$0.03 | -$0.03 - -$0.03 | +33.33% | Beat | N/A | 1 | 0 up, 0 down | Mar 31, 2022 | $2.85M |
| Sep 30, 2021 | -$0.03 | -$0.03 | -$0.03 - -$0.02 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Nov 15, 2021 | $2.11M |
| Jun 30, 2021 | -$0.04 | -$0.02 | -$0.02 - -$0.02 | -100.00% | Miss | N/A | 2 | N/A | Aug 16, 2021 | $2.43M |
| Mar 31, 2021 | -$0.01 | -$0.02 | -$0.03 - -$0.02 | +50.00% | Beat | N/A | 2 | N/A | Apr 1, 2021 | $2.92M |
| Dec 31, 2020 | -$0.01 | -$0.02 | -$0.02 - -$0.02 | +50.00% | Beat | N/A | 2 | N/A | Mar 31, 2021 | $2.21M |
| Sep 30, 2020 | -$0.02 | -$0.04 | -$0.05 - -$0.04 | +50.00% | Beat | N/A | 2 | N/A | Nov 17, 2020 | $1.25M |
| Jun 30, 2020 | -$0.06 | -$0.04 | -$0.04 - -$0.04 | -50.00% | Miss | N/A | 1 | N/A | Aug 14, 2020 | $167674 |
| Mar 31, 2020 | -$0.03 | -$0.02 | -$0.02 - -$0.02 | -50.00% | Miss | N/A | 1 | N/A | May 15, 2020 | $1.81M |
| Dec 31, 2019 | -$0.05 | -$0.02 | N/A | -150.00% | Miss | -600.0% | N/A | N/A | Mar 30, 2020 | $2.30M |
| Sep 30, 2019 | -$0.06 | -$0.01 | -$0.01 - -$0.01 | -500.00% | Miss | N/A | 1 | N/A | Nov 14, 2019 | $1.90M |
| Jun 30, 2019 | -$0.02 | -$0.02 | -$0.02 - -$0.02 | 0.00% | In line | N/A | 1 | N/A | Aug 14, 2019 | $2.26M |
| Mar 31, 2019 | -$0.02 | -$0.04 | -$0.04 - -$0.04 | +50.00% | Beat | N/A | 1 | N/A | Apr 1, 2019 | $1.92M |
| Dec 31, 2018 | $0.01 | -$0.04 | N/A | +125.00% | Beat | N/A | N/A | N/A | Dec 31, 2018 | $3.77M |
| Sep 30, 2018 | -$0.12 | -$0.04 | N/A | -200.00% | Miss | N/A | N/A | N/A | Nov 15, 2018 | $1.62M |
| Jun 30, 2018 | -$0.04 | -$0.05 | -$0.05 - -$0.05 | +20.00% | Beat | N/A | 1 | N/A | Aug 14, 2018 | $2.43M |
| Mar 31, 2018 | -$0.06 | -$0.02 | -$0.02 - -$0.02 | -200.00% | Miss | N/A | 1 | N/A | Apr 3, 2018 | $1.81M |
| Sep 30, 2017 | -$0.04 | -$0.04 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 15, 2017 | $2.85M |
| Jun 30, 2017 | -$0.05 | -$0.05 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 14, 2017 | $2.52M |
| Mar 31, 2017 | -$0.02 | -$0.06 | N/A | +66.67% | Beat | N/A | N/A | N/A | Apr 3, 2017 | $3.69M |
| Dec 31, 2016 | -$0.06 | -$0.05 | N/A | -20.00% | Miss | N/A | N/A | N/A | Mar 31, 2017 | $1.35M |
| Sep 30, 2016 | -$0.05 | -$0.02 | N/A | -150.00% | Miss | N/A | N/A | N/A | Nov 9, 2016 | $3.19M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.06, after -$0.09 the year before. It was -$0.27 for the year ended Dec 31, 2015, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.06 | N/A |
| Dec 31, 2024 | -$0.09 | N/A |
| Dec 31, 2023 | -$0.10 | N/A |
| Dec 31, 2022 | -$0.13 | N/A |
| Dec 31, 2021 | -$0.10 | N/A |
| Dec 31, 2020 | -$0.12 | N/A |
| Dec 31, 2019 | -$0.15 | N/A |
| Dec 31, 2018 | -$0.32 | N/A |
| Dec 31, 2016 | -$0.20 | N/A |
| Dec 31, 2015 | -$0.27 | N/A |
Earnings Calls
The 5 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,000 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 4,973 | 8 | |
| 2025Q4 | Dec 31, 2025 | 2,768 | 7 | |
| 2025Q3 | Sep 30, 2025 | 4,027 | 7 | |
| 2024Q3 | Sep 30, 2024 | 4,085 | 6 | |
| 2024Q2 | Jun 30, 2024 | 4,170 | 5 |
2026Q1 Earnings Call
Opening remarks
James Carbonara Investor Relations Thank you, operator. Before we begin, please note that today's call will contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Please refer to our earnings press release as well as our filings with the SEC, including our 2025 Form 10-K for a discussion of these risks. A replay of this call will be available shortly after its conclusion. With that, I'll turn the call over to our CEO, Eric Hines.
Eric Hines Chief Executive Officer Thank you, James, and good morning, everybody, and thank you for joining our call today. I especially want to thank everybody who participated in our PIPE in April and your continued support for Milestone. It is greatly appreciated. Our first quarter results reflect continued progress as we execute on the foundation we established in 2025. We remain focused on building a disciplined operating model where spending is aligned with revenue generation and clear return on investment. That focus is reflected in our results. We maintained a relatively stable revenue base in the quarter despite the inability to ship certain booked orders to the Middle East due to the ongoing global conflict in the region. Even with that headwind, we reduced operating expenses by approximately $1.3 million or more than 30% year-over-year, significantly narrowing our losses while we align the company for growth. At the same time, we are beginning to see early signs of traction in the areas that we see as key growth drivers. Starting with our dental business, which remains the backbone of the company. We continue to execute on the national rollout of our ambassador program following its expansion in January, resulting in 173 applications, 73 active ambassadors and 25 new demos and multiple new sales. Engagement levels have been encouraging. And while we expect the financial impact to build over time, we believe this initiative is strengthening our commercial presence and positioning us for improved performance in the back half of the year. Internationally, we continue to pursue additional registrations, which we believe can open meaningful new markets over time. Turning to the medical side. CompuFlo continues to gain traction and is becoming an increasingly important part of our growth strategy. In the first quarter, medical revenue more than doubled year-over-year, reflecting early-stage adoption and growing interest from clinicians. While we are still in the early innings, the progress reinforces our view that the CompuFlo represents a significant long-term opportunity for the company. We also continue to build our infrastructure required to support that growth.
Frequently Asked Questions About MLSS
When is Milestone Scientific's next earnings date?
Milestone Scientific's next earnings report is expected for Mar 29, 2027.
Did MLSS beat earnings estimates last quarter?
Milestone Scientific reported EPS of -$0.01 for the quarter ended Sep 30, 2026, in line with the -$0.01 estimate.
What EPS do analysts expect from MLSS next quarter?
The consensus EPS estimate for Milestone Scientific for the quarter ending Dec 31, 2026 is -$0.01 from 4 analysts, with estimates from -$0.01 to -$0.01.
How often does MLSS beat earnings estimates?
Milestone Scientific beat the EPS estimate in 0 of the last 8 quarters, with an average surprise of -50.00%.
MLSS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors